- Home
- / Guardant Health
Guardant Health
Stock Price
$24.2
2023-11-24
Market Capitalization
$2.7 B
2023-11-23
Revenue
$449.5 M
FY, 2022
Guardant Health Summary
Company Summary
- Overview
- Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Its digital sequencing technology provides a picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Redwood City, CA, US | view all locations
- Website
- https://guardanthealth.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ian Clark, Lead Independent Director
AmirAli Talasaz, Co-Chief Executive Officer and Director
Kumud Kalia, Chief Information Officer
Operating MetricsView all
Facilities Leased, sq. ft.
163K
FY, 2021
Tests to Clinical Customers Sold
87.6K
38.5%
FY, 2021
Tests to Biopharmaceutical Customers Sold
18.6K
16.4%
FY, 2021
Guardant Health Financials
Summary Financials
- Revenue (Q2, 2023)
- $137.2M
- Net income (Q2, 2023)
- ($72.8M)
- Cash (Q3, 2023)
- $457.3M
- EBIT (Q2, 2023)
- ($119.6M)
- Enterprise value
- $3.4B